C3495436||American cutaneous leishmaniasis
C0301872||immune response
C0332665||recent
C0221198||lesions
C1456820||TNF-α
C0021745||IFN-γ
C0085295||IL-10
C0384648||IL-17
C0108799||CD68
C0054965||CD57
C0220825||evaluated
C0005558||biopsies
C3495436||American cutaneous leishmaniasis
C0017446||Sorocaba
C0006137||Brazil
C0936012||analyses
C0221198||lesions
C0332665||recent lesions
C1257890||Group I
C0221198||lesions
C1257890||Group II
C0439663||infected
C0023271||Leishmania (Viannia) braziliensis
C0022885||Immunostaining
C0007634||cells
C0108799||CD68
C0054965||CD57
C1456820||TNF- α
C0021745||IFN-γ
C0085295||IL-10
C0384648||IL-17
C0021044||immunohistochemistry
C0108799||CD68
C0384648||IL-17
C0054965||CD57
C0085295||IL-10
C1456820||TNF-α
C0021745||IFN-γ
C0332665||recent lesions
C0221198||lesions
C0079189||cytokine
C1171362||expression
C0085295||IL-10
C0384648||IL-17
C0021745||IFN-γ
C0384648||IL-17
C1456820||TNF-α
C0014653||balance
C0003209||anti-inflammatory agents
C0014653||balance
C1257890||groups
C1257890||Group I
C0332665||recent lesions
C1257890||Group II
C1155266||inflammatory response
C3495436||American cutaneous leishmaniasis
C0085295||IL-10
C1171362||expression
C0037284||skin lesions
C0243107||development
C0574771||mucosal forms
C0030498||parasite
C0087111||treatment
C1854779||severe forms